LincRNA FEZF1-AS1 contributes to the proliferation of LAD cells by silencing p57 expression

Shuai Jin; Siyu Chen; Yongfu Ma; Bo Yang; Yang Liu

doi:10.18632/oncotarget.21265

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

LincRNA FEZF1-AS1 contributes to the proliferation of LAD cells by silencing p57 expression

Shuai Jin, Siyu Chen, Yongfu Ma, Bo Yang and Yang Liu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:103004-103013. https://doi.org/10.18632/oncotarget.21265

Metrics: PDF 1119 views | HTML 2001 views | ?

Abstract

Shuai Jin1, Siyu Chen1, Yongfu Ma1, Bo Yang1 and Yang Liu1

1Department of Thoracic surgery, PLA General Hospital, Beijing, 100853 China

Correspondence to:

Yang Liu, email: [email protected]

Keywords: lung adenocarcinoma, FEZF1-AS1, LSD1, EZH2, H3K4me2

Received: May 23, 2017 Accepted: September 05, 2017 Published: September 23, 2017

ABSTRACT

LincRNA FEZF1-AS1 has been identified to exert oncogenic functions in various biological processes of tumorigenesis. However, the function of FEZF1-AS1 in lung adenocarcinoma still remains unclear. Our findings revealed that FEZF1-AS1 was increased in lung adenocarcinoma tissues and cell lines and high level of FEZF1-AS1 was associated with poor prognosis of lung adenocarcinoma. Functional experiments and mechanistic investigations demonstrated that knockdown of FEZF1-AS1 significantly repressed proliferation through influencing the distribution of cell cycle. Besides, we also uncovered that FEZF1-AS1 could suppress p57 expression through recruiting EZH2 and LSD1 to the promoter of p57, thus influenced the cell cycle and proliferation. Collectively, our results suggested that FEZF1-AS1 was involved in the progression of lung adenocarcinoma and might be as a potential therapy target for human lung adenocarcinoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21265

Publication Alerts

Research Papers:

LincRNA FEZF1-AS1 contributes to the proliferation of LAD cells by silencing p57 expression

Abstract